Hematological Clozapine Monitoring With a Point-of-care Device (CHEMPAQ)

University of Aarhus85 enrolled

Overview

Clozapine remain the drug of choice for treatment resistant schizophrenia and up to 60% of patients not responding to other antipsychotics will respond to clozapine. However, the use of clozapine is restricted due to the risk of agranulocytosis and consequently the need for mandatory hematological monitoring. CHEMPAQ XBC is a point-of-care device that can be used in patients home and analyze WBC and granulocytes by a single capillary blood drop. This study aims to investigate whether this new procedure increases the acceptability of clozapine

Study Type

OBSERVATIONAL

Enrollment

Conditions

Schizophrenia

Interventions

Venous blod sampleDEVICE

Regular venous blood sample withdrawn from the laboratory

CHEMPAQDEVICE

Capillary blood sample analyzed by CHEMPAQ

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Treated with clozapine * Compliant with blood monitoring * Willing to give informed consent Exclusion Criteria: * Prior case of agranulocytosis

Locations (6)

Psychiatric Center Roskilde

Greve, Greve, Denmark

Aalborg Psychiatric Hospital

Aalborg, Denmark

Psychiatric Center Aarhus

Aarhus, Denmark

Psychiatric Center Copenhagen

Copenhagen, Denmark

Outcomes

Primary Outcomes

Pain sensation

Pain sensation was measured using a visual analog scale (VAS)

Time frame: Monthly for four months

Secondary Outcomes

The benefits of CHEMPAQ

Caregivers and patients were asked about the benefits of using CHEMPAQ for hematological clozapine monitoring.

Time frame: Monthly for four months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.